Trial Site Detail

 

Drug:
BAY80-6946 + BAY86-9766
Trial:
Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer
Conditions: Solid Tumors
Trial Status:
Ongoing, but not recruiting

 

MD Anderson Cancer Center

1505 Holcombe Blvd.     
Houston , TX 77030
USA

 

Principal Investigator:
Contact:
Activation Status of this Site:
Closed
Notes about this Site:
MD Anderson Cancer Center Website:
http://www.mdanderson.org/Cancer_Pro/CS_Resources/display.cfm?id=562561A1-751F-11D4-AEBD00508BDCCE3A&method=displayFull

 

 

Navigating the Map

Use the plus (+) and minus (-) controls to zoom in/out.

Click and drag the map or use the arrows to move (pan) the map.

Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.